Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria
Open Access
- 1 May 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (5), 2493-2503
- https://doi.org/10.1128/aac.06305-11
Abstract
The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains of Clostridium difficile and 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity against C. difficile and most other Gram-positive anaerobes (MIC 90 , ≤0.25 μg/ml), with the exception of bifidobacteria and lactobacilli. The MIC 90 s for aerobes, including enterococci, Staphylococcus aureus (as well as methicillin-resistant S. aureus [MRSA] isolates), Streptococcus pyogenes , and other streptococci were 0.06, 0.125, 2, and 8 μg/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC 90 s against C. difficile , Clostridium perfringens , and Bifidobacterium spp. were 0.5, ≤0.015, and 0.125 μg/ml, respectively, but >32 μg/ml against Clostridium ramosum and Clostridium innocuum . MIC 90 for S. pyogenes and other streptococci was 16 and >32 μg/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes.Keywords
This publication has 21 references indexed in Scilit:
- Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile InfectionAntimicrobial Agents and Chemotherapy, 2011
- Biology of Clostridium difficile: Implications for Epidemiology and DiagnosisAnnual Review of Microbiology, 2011
- Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via ColonoscopyJournal of Clinical Gastroenterology, 2010
- Clostridium difficile infection: new developments in epidemiology and pathogenesisNature Reviews Microbiology, 2009
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- Emergence of reduced susceptibility to metronidazole in Clostridium difficileJournal of Antimicrobial Chemotherapy, 2008
- Editorial Commentary:Decreased Effectiveness of Metronidazole for the Treatment ofClostridium difficileInfection?Clinical Infectious Diseases, 2008
- Comparison of Clinical and Microbiological Response to Treatment ofClostridium difficile–Associated Disease with Metronidazole and VancomycinClinical Infectious Diseases, 2008
- Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. Isolated from Human Clinical InfectionsJournal of Clinical Microbiology, 2006
- Manual of Clinical Microbiology, 8th Edition:Manual of Clinical Microbiology, 8th EditionClinical Infectious Diseases, 2004